The test did not reach the end point of juxtaposed main effectiveness; there were no new safety warnings.

Cambridge, Massachusetts, USA and Beijing, China April 8 / PRNewswire-Asianet /-- Baiji China (Nasdaq: BGNE; SEHK: 06160) is a commercial biotechnology company focused on the development and commercialization of innovative drugs worldwide. The company announced today that a study aimed at evaluating Baiyue Ze^®(zabutinib) the phase 2 clinical trial of placebo for inpatients with COVID-19 ("COVID-19") and requiring non-mechanical ventilation did not reach the main end point of survival without respiratory failure or reduced days of oxygen inhalation. Baiyueze^®There is no new safety warning in the test.

Huang Weijuan, Chief Medical Officer of Baiji Shenzhou Hematology, said: "through the efforts of the Baiji Shenzhou team and our research partners, we have been able to learn more about the potential of BTK inhibitors against novel coronavirus, and I am also proud of it. Although the results of this phase 2 clinical trial are not satisfactory, in order to evaluate Baiyue Ze^®The speed with which the clinical trial can be launched to contribute to the global fight against COVID-19 is gratifying. Baiji China's mission has always been to find treatments to help patients around the world under the guidance of rigorous science and in well-designed and conducted trials. "

Baiji China is expected to submit relevant data in the form of scientific reports or academic papers in the future.